Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Surgery, Skin Cancer, Suture; Complications, Infection or Inflammation
Interventions: Wound Closure with sutures vs staples; Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Metastatic Prostate Cancer
Interventions: High dose testosterone; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 17
States / cities: Aurora, Colorado • West Haven, Connecticut • Gainesville, Florida + 14 more

Conditions: Leukemia
Interventions: filgrastim, recombinant interferon alfa, cyclophosphamide, cytarabine, etoposide, idarubicin, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Loyola University; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 3
States / cities: Chicago, Illinois • Maywood, Illinois

Conditions: Acute Renal Failure
Interventions: Standard dose of dialysis, High dose of dialysis; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
Interventions: Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 3 Years to 17 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 9
States / cities: San Francisco, California • Kansas City, Missouri • Cincinnati, Ohio + 6 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: creatine, tamoxifen; Drug
Lead sponsor: Nazem Atassi; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: Kansas City, Kansas • Boston, Massachusetts • Worcester, Massachusetts + 6 more

Conditions: Prostate Cancer
Interventions: 177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more

Conditions: Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine, Busulfan, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Pharmacological Study, Tacrolimus; Procedure · Biological · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 74 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 17
States / cities: Lewes, Delaware • Newark, Delaware • Orlando, Florida + 12 more

Conditions: Febrile Neutropenia
Interventions: Alio Smart Patch™; Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Premature Infants
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Months to 24 Months
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: busulfan, cyclophosphamide, etoposide, allogeneic bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 15 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hematopoietic Stem Cell Transplant
Interventions: Vitamin A; Dietary Supplement
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension, Cardiovascular Diseases, Diabetes Mellitus, Metabolic Syndrome X
Interventions: Not listed
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 2,072 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Tobacco Use
Interventions: Behavior Therapy; Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 20
States / cities: Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more

Conditions: Gastric Cancer
Interventions: Molecular testing for all participants., Germline Testing, Survey; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Interventions: DS-8201a, T-DM1; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 126
States / cities: Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more

Conditions: Leukemia, Myeloid, Chronic
Interventions: Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma, HIV
Interventions: Autologous transplant, BCNU, Etoposide, Cytarabine, Melphalan; Procedure · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 15 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 16
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 10 more

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 17
States / cities: Los Angeles, California • Santa Clarita, California • New Haven, Connecticut + 14 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Pomalidomide, Carfilzomib, Dexamethasone; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Encinitas, California • Fountain Valley, California • Monterey, California + 3 more

Conditions: HIV
Interventions: Standard Referral, Project Bridge; Behavioral
Lead sponsor: RTI International; Other
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Malignant Glioma
Interventions: Hydrogen, Placebo oral tablet; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 65 Years and older
Enrollment: 414 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 5
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 2 more

Search by objective public record fields.

A Randomized Controlled Trial Comparing Sutures vs Staples for High Tension Closures

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia

High Dose CVVHDF Compared to Standard Dose CVVHDF

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

ECM and Monitoring w/ Alio Smart Patch in Cancer Pts Receiving Chemotherapy

Post-Discharge Growth and Development of Infants Who Received Targeted Fortification in the NICU

Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma

Vitamin A Replacement in Patients Undergoing HSCT and Its Role on MBI-LCBI Rates

Cardiovascular Disease Risk Factors in Chinese American Immigrants

Early Tobacco Abstinence - 5

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Autologous Transplant in HIV Patients (BMT CTN 0803)

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Combination Study for High Risk Multiple Myeloma Patients

Urban Health Study II

Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.

Eldery High Dose TIV 2005